AbbVie’s troubled $10B Rova-T cancer drug program takes a sudden turn toward the cliff
The Rova-T problem at AbbVie may be headed toward a full-fledged disaster.
Researchers slammed the brakes on one of their Phase III studies of the $10 billion drug after an independent group of monitors determined that their drug was linked to a shorter overall survival rate than the chemo drug used in the control arm.
Basic subscription required
Unlock this story instantly and join 53,100+ biopharma pros reading Endpoints daily — and it's free.